Jay Feist, DPM
NPI 1740374172 · Podiatrist · Cincinnati, OH
Enrolled with Medicare as Practitioner - Podiatry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1740374172
- Entity type
- Individual
- Primary specialty
- PodiatristPodiatric Medicine & Surgery Service Providers
- Credential
- DPM
- Sex
- Male
- Sole proprietor
- No
- License
- 36002650 (OH)
Specialties & taxonomies
Podiatric Medicine & Surgery Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
4,213 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Removal of Fingernails Or Toenails, 1-5 Nails11720 | 1,053 | $32 |
| Trimming of Dystrophic Nails, Any NumberG0127 | 756 | $13 |
| Removal of Fingernails Or Toenails, 6 Or More Nails11721 | 451 | $44 |
| Removal of Noncancer Thickened Skin Growth, 2-4 Growths11056 | 402 | $79 |
| Removal of Noncancer Thickened Skin Growth, 1 Growth11055 | 391 | $68 |
| Established Patient Office Or Other Outpatient Visit With Straightforward Medical Decision Making, If Using Time, 10 Minutes Or More99212 | 351 | $56 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 7 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Diclofenac Sodium | 46 | 20 |
| Gabapentin | 22 | — |
| Amoxicillin | 22 | 14 |
| Terbinafine Hcl | 17 | 16 |
| Allopurinol | 15 | — |
| Ciclopirox | 12 | — |
| Tramadol Hcl | 12 | — |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means , never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$683 across 12 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-10-02
- Last updated
- 2020-07-29
- Certified
- 2020-07-29
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.